Switch theme
Sign up to access all valuation multiples
GuangYuYuan Chinese Herbal Medicine Co Ltd distributes pharmaceutical products. Its products include far plate turtle age wine bottle, niuhuang qingxin pills, boutique angong niuhuang wan, modified turtle age wine, ding kundan, and many more.
1996
3.1K+
LTM Revenue $181M
LTM EBITDA $26.8M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GuangYuYuan Chinese has a last 12-month revenue (LTM) of $181M and a last 12-month EBITDA of $26.8M.
In the most recent fiscal year, GuangYuYuan Chinese achieved revenue of $170M and an EBITDA of $19.5M.
GuangYuYuan Chinese expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GuangYuYuan Chinese valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $181M | XXX | $170M | XXX | XXX | XXX |
| Gross Profit | $134M | XXX | $125M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | $26.8M | XXX | $19.5M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 12% | XXX | XXX | XXX |
| EBIT | $18.8M | XXX | $25.7M | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $13.1M | XXX | $10.3M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, GuangYuYuan Chinese's stock price is CNY 22 (or $3).
GuangYuYuan Chinese has current market cap of CNY 10.6B (or $1.5B), and EV of CNY 10.4B (or $1.4B).
See GuangYuYuan Chinese trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.5B | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, GuangYuYuan Chinese has market cap of $1.5B and EV of $1.4B.
GuangYuYuan Chinese's trades at 8.5x EV/Revenue multiple, and 74.1x EV/EBITDA.
Equity research analysts estimate GuangYuYuan Chinese's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GuangYuYuan Chinese has a P/E ratio of 112.3x.
See valuation multiples for GuangYuYuan Chinese and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 8.0x | XXX | 8.5x | XXX | XXX | XXX |
| EV/EBITDA | 53.9x | XXX | 74.1x | XXX | XXX | XXX |
| EV/EBIT | 76.9x | XXX | 56.2x | XXX | XXX | XXX |
| EV/Gross Profit | 10.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 112.3x | XXX | 142.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 100.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGuangYuYuan Chinese's last 12 month revenue growth is 17%
GuangYuYuan Chinese's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $32K for the same period.
GuangYuYuan Chinese's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GuangYuYuan Chinese's rule of X is 56% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for GuangYuYuan Chinese and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 33% | XXX | 28% | XXX | XXX | XXX |
| Rule of 40 | 28% | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $32K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GuangYuYuan Chinese acquired XXX companies to date.
Last acquisition by GuangYuYuan Chinese was XXXXXXXX, XXXXX XXXXX XXXXXX . GuangYuYuan Chinese acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was GuangYuYuan Chinese founded? | GuangYuYuan Chinese was founded in 1996. |
| Where is GuangYuYuan Chinese headquartered? | GuangYuYuan Chinese is headquartered in China. |
| How many employees does GuangYuYuan Chinese have? | As of today, GuangYuYuan Chinese has 3.1K+ employees. |
| Is GuangYuYuan Chinese publicy listed? | Yes, GuangYuYuan Chinese is a public company listed on SHG. |
| What is the stock symbol of GuangYuYuan Chinese? | GuangYuYuan Chinese trades under 600771 ticker. |
| When did GuangYuYuan Chinese go public? | GuangYuYuan Chinese went public in 1996. |
| Who are competitors of GuangYuYuan Chinese? | Similar companies to GuangYuYuan Chinese include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of GuangYuYuan Chinese? | GuangYuYuan Chinese's current market cap is $1.5B |
| What is the current revenue of GuangYuYuan Chinese? | GuangYuYuan Chinese's last 12 months revenue is $181M. |
| What is the current revenue growth of GuangYuYuan Chinese? | GuangYuYuan Chinese revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of GuangYuYuan Chinese? | Current revenue multiple of GuangYuYuan Chinese is 8.0x. |
| Is GuangYuYuan Chinese profitable? | Yes, GuangYuYuan Chinese is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of GuangYuYuan Chinese? | GuangYuYuan Chinese's last 12 months EBITDA is $26.8M. |
| What is GuangYuYuan Chinese's EBITDA margin? | GuangYuYuan Chinese's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of GuangYuYuan Chinese? | Current EBITDA multiple of GuangYuYuan Chinese is 53.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
